Analysis

PhRMA: resetting the conversation

PhRMA: resetting the conversation

Do healthcare cuts risk creating a ‘desert for innovation’ in the UK?

Do healthcare cuts risk creating a ‘desert for innovation’ in the UK?

Pharma Technology Focus – Issue 61

Pharma Technology Focus – Issue 61

Cystic fibrosis: searching for a breakthrough

Cystic fibrosis: searching for a breakthrough

Treating mononucleosis: why the mystery?

Treating mononucleosis: why the mystery?

Reforming paediatric cancer trials in Europe

Reforming paediatric cancer trials in Europe

Immuno-oncology: where to go in a packed field

Immuno-oncology: where to go in a packed field

Sealed with a kisspeptin: the clinical potential of the ‘love hormone’

Sealed with a kisspeptin: the clinical potential of the ‘love hormone’

Pharma Technology Focus – Issue 60

Pharma Technology Focus – Issue 60

Counting the cost of failure in drug development

Counting the cost of failure in drug development

The gene-silencing approach to cutting cholesterol

The gene-silencing approach to cutting cholesterol

Pooling resources for clinical trials

Pooling resources for clinical trials

Micro-machines: nanotech offers new possibilities for disease detection and drug delivery

Micro-machines: nanotech offers new possibilities for disease detection and drug delivery

Pharma Technology Focus – Issue 59

Pharma Technology Focus – Issue 59

Challenging the link between pharma innovation and US drug pricing

Challenging the link between pharma innovation and US drug pricing

Pharma Technology Focus – Issue 58

Pharma Technology Focus – Issue 58

Cancergraph: a desperately needed link between patient and clinical trial

Cancergraph: a desperately needed link between patient and clinical trial

Pharma Technology Focus – Issue 57

Pharma Technology Focus – Issue 57

Turning to turmeric: exciting drug candidate or another dead end?

Turning to turmeric: exciting drug candidate or another dead end?

Learning from tragedy: safety and dosing in first-in-human trials

Learning from tragedy: safety and dosing in first-in-human trials

Using shark antibodies to treat Alzheimer’s disease

Using shark antibodies to treat Alzheimer’s disease
cachename:Featurescachekey:rd-137342983_1031809799_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_1492331643